Diabetes-Metabolism Research and Reviews最新文献

{"title":"Clinical and Metabolic Predictors of Cognitive Impairment in Type 1 Diabetes: The Role of Peripheral Neuropathy and Hypoglycaemia Unawareness. Findings From a HAD-1 Study.","authors":"Magdalena Michalak, Dorota Zozulińska-Ziółkiewicz, Michał Michalak, Justyna Flotyńska, Aleksandra Cieluch, Mateusz Michalski, Aleksandra Araszkiewicz","doi":"10.1002/dmrr.70180","DOIUrl":"10.1002/dmrr.70180","url":null,"abstract":"<p><strong>Aims: </strong>This study evaluated the impact of selected clinical factors on cognitive impairment (CI), particularly diabetic peripheral neuropathy (DPN) and impaired awareness of hypoglycaemia (IAH) in individuals with long-standing type 1 diabetes (T1D).</p><p><strong>Materials and methods: </strong>In this cross-sectional Hypoglycaemia Awareness Study in Diabetes Type 1 (HAD-1), 252 adults with T1D were enrolled. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), with CI defined as a MoCA score < 26. IAH was identified using validated questionnaires (Clarke scale, Gold scale and Hypoglycaemia Awareness Questionnaire).</p><p><strong>Results: </strong>The median MoCA score was 26 (23-28). CI was present in 122 subjects (48%), DPN in 85 subjects (34%) and IAH in 98 patients (39%). In univariate linear regression analysis, lower MoCA scores were associated with higher HbA1c (β = -0.30 and p = 0.017), older age (β = -0.03 and p = 0.014), a greater number of lifetime severe hypoglycaemia (SH) episodes (β = -0.17 and p = 0.001), DPN (β = -1.09 and p = 0.01) and higher skin autofluorescence (β = -0.72 and p = 0.03). In the multivariable regression analysis, IAH (β = -1.41 and p < 0.001), male sex (β = -0.89 and p = 0.022), higher HbA1c (β = -0.47 and p < 0.001) and higher vibration perception threshold (β = -0.049 and p = 0.004) were independent predictors of lower cognitive performance. Higher insulin dose (β = +2.92 and p = 0.012) was independently associated with better cognitive performance. In the interaction model, IAH (β = -1.54 and p = 0.003) and DPN (β = -1.18, p = 0.040) were independently associated with approximately 1.2-1.5-point lower MoCA scores.</p><p><strong>Conclusions: </strong>In individuals with T1D, DPN and IAH, a history of SH, poorer metabolic control, older age and male sex are associated with CI. People with T1D should be screened for CI, especially if they have DPN or IAH.</p>","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"42 4","pages":"e70180"},"PeriodicalIF":6.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179733/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147960538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety.","authors":"Yonglu Hu, Chengqian Li, Shufa Li, Lili Xu, Yangang Wang, Bingzi Dong","doi":"10.1002/dmrr.70075","DOIUrl":"10.1002/dmrr.70075","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a major global health issue that significantly impacts patients' quality of life and places a substantial burden on healthcare systems. Overactivation of the mineralocorticoid receptor (MR) plays a crucial role in kidney damage by promoting inflammation, fibrosis, and functional deterioration. Finerenone, a third-generation highly selective non-steroidal MR antagonist (MRA), has emerged as a promising therapeutic option for CKD. In this review, we discuss the mechanisms through which MR overactivation contributes to renal damage, the structural and pharmacokinetic characteristics of finerenone, and compare it with first- and second-generation MRAs. We also focus on the safety and efficacy of finerenone in clinical applications for CKD. Notably, finerenone demonstrated a reduction in the risk of hyperkalemia during treatment, with its high selectivity minimising treatment-related hormonal imbalances, offering a novel perspective. Furthermore, we explore the promising future of finerenone in both diabetic kidney disease (DKD) and non-diabetic CKD, presenting updates from recent clinical trials and new insights into its potential role in these populations. In clinical practice, combining finerenone with sodium-glucose cotransporter-2 (SGLT-2) inhibitors and renin-angiotensin system (RAS) inhibitors has demonstrated strong cardiorenal protective effects. However, further clinical evidence is needed regarding direct combinations of finerenone with RAS inhibitors. Future studies on their synergistic effects may provide valuable insights. Ultimately, we hope this review offers new perspectives on finerenone's clinical applications and its future therapeutic prospects.</p>","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 6","pages":"e70075"},"PeriodicalIF":6.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alternations of Gut Microbiome and Serum Metabolome With Prolongation of the Course of Type 1 Diabetes Mellitus.","authors":"Jiayu Li, Xuedi Chen, Hang Min, Zouxi Du, Leyuan Zhang, Wenting Hua, Limin Tian","doi":"10.1002/dmrr.70076","DOIUrl":"10.1002/dmrr.70076","url":null,"abstract":"<p><strong>Aims: </strong>We aimed to explore the gut microbial and serum metabolic disturbances associated with the course of type 1 diabetes mellitus (T1DM), and identify potential biomarkers for discriminating T1DM from normoglycemia individuals by machine learning.</p><p><strong>Methods: </strong>We performed 16s ribosomal RNA gene sequencing and untargeted metabolomics in a cohort of 41 patients with T1DM of varying diabetes duration and 39 healthy controls (HCs) to characterise complex interactions between the gut microbiome and serum metabolome during T1DM progression.</p><p><strong>Results: </strong>We identified 25 microbial genera that significantly altered in patients with T1DM, eight genera changed as the disease course, and 17 genera changed only in a specific T1DM-course group. Metabolomics analysis revealed that serum glycerophospholipid and amino acids levels were significantly changed in T1DM patients with varying disease course. Notably, we observed significantly higher levels of serum estrone, whereas lower levels of corticosterone and estrone glucuronide as the course of T1DM prolonged; Glycated haemoglobin and fasting blood glucose levels were positively correlated with estrone, and negatively correlated with corticosterone and estrone glucuronide. Furthermore, these notably changes in gut microbiota and serum metabolome were accompanied by functional alterations in sphingolipid, glutathione and taurine and hypotaurine metabolism pathways with T1DM progression. Finally, we successfully selected seven microbial and three metabolic biomarkers to differentiate T1DM from HCs.</p><p><strong>Conclusions: </strong>Perturbed diabetes course-related gut microbiota was highly correlated with the alternation of metabolic patterns in T1DM, and multi-omics coupled with machine learning algorithms can be used to develop diagnostic models based on selected biomarkers.</p>","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 6","pages":"e70076"},"PeriodicalIF":6.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Letter to the Editor - responses to Weisntein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and antiactivity in cultured cancer cells.","authors":"","doi":"10.1002/dmrr.2447","DOIUrl":"10.1002/dmrr.2447","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2447"},"PeriodicalIF":6.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Screening for people with glucose metabolism disorders within the framework of the DEMOJUAN project (DEMOnstration area for primary prevention of type 2 diabetes, JUAN Mina and Barranquilla, Colombia).","authors":"","doi":"10.1002/dmrr.2462","DOIUrl":"10.1002/dmrr.2462","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2462"},"PeriodicalIF":8.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Prevalence of type 2 diabetes in Argentina 1979-2012.","authors":"","doi":"10.1002/dmrr.2436","DOIUrl":"10.1002/dmrr.2436","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2436"},"PeriodicalIF":6.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Can we prevent beta cell apoptosis in type 2 diabetes?","authors":"","doi":"10.1002/dmrr.2381","DOIUrl":"10.1002/dmrr.2381","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2381"},"PeriodicalIF":8.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications.","authors":"","doi":"10.1002/dmrr.2442","DOIUrl":"10.1002/dmrr.2442","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2442"},"PeriodicalIF":6.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Withdrawal: Do we need continuous glucose monitoring in type 2 diabetes?","authors":"","doi":"10.1002/dmrr.2450","DOIUrl":"10.1002/dmrr.2450","url":null,"abstract":"","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 4","pages":"e2450"},"PeriodicalIF":8.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Quantitative Neuropad for Early Diagnosis of Diabetic Peripheral Neuropathy.","authors":"Zheng Yang, Subei Zhao, Yuhuan Lv, Linyu Xiang, Xiaoru Zhang, Zhengping Feng, Zhiping Liu, Rong Li","doi":"10.1002/dmrr.70010","DOIUrl":"https://doi.org/10.1002/dmrr.70010","url":null,"abstract":"<p><strong>Aims: </strong>Diabetic peripheral neuropathy (DPN) often coexists with sudomotor dysfunction, resulting in an increased risk of diabetic foot. This study aimed to explore an efficient method for early diagnosis of DPN by establishing a quantitative Neuropad.</p><p><strong>Methods: </strong>We recruited 518 patients with type 2 diabetes. Neuropathy Symptoms Score (NSS) combined with Neuropathy Disability Score (NDS) was used to assess distal symmetrical peripheral neuropathy (DSPN). The area under the ROC curve (AUROC), sensitivity, and specificity were used to compare the diagnostic efficacy of quantitative Neuropad (the change rate of the chromatic aberration value per minute) and two types of visual Neuropad (visual Neuropad A: whether the time to complete colour change within 10 min, visual Neuropad B: the time to complete colour change) for DPN.</p><p><strong>Results: </strong>We did not observe very good diagnostic efficacy of Neuropad (visual Neuropad A and B: 0.59 and 0.64, quantitative Neuropad AUROC: 0.62-0.64) when using standard DSPN diagnostic criteria (NDS 6-12 or NDS 3-5 combined with NSS 5-9). When DPN was assessed by NSS + NDS ≥ 4, visual Neuropad B improved the specificity (AUROC 0.72, 67.00%, specificity 71.70%) by extending the detection time compared with visual Neuropad A (AUROC 0.62, sensitivity 81.80%, specificity 41.70%). Quantitative Neuropad significantly improved the diagnostic effect (AUROC 0.81, sensitivity 80.0%, specificity 76.3%) and reduced the detection time (4 min).</p><p><strong>Conclusions: </strong>This study provides a new quantitative Neuropad, which has great potential to be an extremely useful diagnostic tool for early screening of sudomotor dysfunction in the clinical practice.</p>","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"40 8","pages":"e70010"},"PeriodicalIF":8.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}